相关实验视频
Updated: Jan 18, 2026

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
819
临床阿尔茨海默病研究和诊断当前的方法
Eleftheria Kodosaki1,2, Henrik Zetterberg1,2,3,4,5,6, Amanda Heslegrave7,8
1Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
Molecular diagnosis & therapy
|June 7, 2025
概括
早期阿尔茨海默病 (AD) 诊断至关重要. 新的分子和成像工具提高了检测,但成本和标准化等挑战阻碍了广泛的临床使用,以改善患者的治疗结果.
科学领域:
- 神经学 神经学
- 生物标志物发现发现
- 医疗成像医学成像
背景情况:
- 早期和准确的阿尔茨海默病 (AD) 诊断对于及时干预和改善患者结果至关重要.
- 最近分子和成像技术的进步提高了早期AD检测和研究质量.
- 关键的分子标志包括粉样β斑块和tau蛋白,这是AD病理学的核心.
研究的目的:
- 讨论改善早期AD诊断有效性的必要性.
- 审查正在进行的研究,改进生物标志物检测和成像技术.
- 探索开发更具成本效益的非侵入性诊断方法.
主要方法:
- 对生物流体样本进行生物标志物检测的分析 (例如,粉素-β,tau).
- 应用先进的成像方法在体内生物标志物可视化.
- 讨论当前的挑战,包括标准化,可访问性,成本和专业知识要求.
主要成果:
- 分子和成像方法为生物标志物检测提供高灵敏度,但具有相关的缺点.
- 一些方法已经过渡到临床实践,但标准化和可访问性仍然是重大障碍.
- 高昂的成本和专业的专业知识被认为是广泛采用的主要障碍.
结论:
- 提高早期阿尔茨海默病诊断的有效性至关重要.
- 目前正在进行的研究重点是改进生物标志物检测和增强成像技术.
- 开发具有成本效益的非侵入性诊断工具对于更广泛的临床应用至关重要.
更多相关视频
12:28Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
18.1K
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
28.0K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827
Dementia
526
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
526